跳至主要内容
临床试验/NCT00272207
NCT00272207已完成2 期

A Randomized Double-blinded Placebo Controlled Trial Assessing the Effect of the Oral Cannabinoid Nabilone on Pain and Quality of Life in Patients With Fibromyalgia

Winnipeg Regional Health Authority2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2006年4月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40
试验地点
2
主要终点
Visual Analogue Scale Pain Scores

研究概览

简要总结

The purpose of the study is to determine whether or not the drug Nabilone significantly reduces pain and improves quality of life in patients with fibromyalgia.

详细描述

Fibromyalgia is a disease of unknown cause. People with fibromyalgia experience diffuse body pain, fatigue, sleep disturbance, and a generalized stiffness and swollen feeling. Fibromyalgia affects 2-6% of the general population, affecting females more commonly than males. Symptoms usually start between 20 and 55 years of age.

No medical treatment has been specifically approved for the management of fibromyalgia, however, there is strong evidence that some antidepressants, exercise, and patient education are effective in reducing the pain experienced by fibromyalgia patients. A recent study of four patients has suggested the possible benefit of Nabilone, a synthetic cannabinoid, in the treatment of fibromyalgia, however more studies are needed.

Marijuana is the common name for cannabis. Nabilone (brand name, CESAMET®), is a synthetic cannabinoid (form of cannabis). Cannabinoid receptors exist naturally in the human body and respond to naturally occurring cannabinoids produced by the body, as well as marijuana and synthetic cannabinoids like Nabilone.

In Canada, Nabilone is approved for the treatment and management of severe nausea and vomiting associated with cancer chemotherapy and may be prescribed by physicians.

Research has shown that activating the cannabinoid receptors also has an effect on reducing acute and chronic pain.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patient meets The American College of Rheumatology (1990) criteria for the classification of fibromyalgia. [5]
  • 18-70 years old.
  • Any gender.
  • The patient has not received benefit from a tricyclic antidepressant, muscle relaxant, acetaminophen or non-steroidal anti-inflammatories for management of their pain.
  • No previous use of oral cannabinoids for pain management.

排除标准

  • The patient's pain is better explained by a diagnosis other then fibromyalgia.
  • Abnormalities on routine baseline blood work including electrolytes, urea and creatinine, a complete blood count, and liver function tests (AST ALT GGT, Alk Phos, and LDH). Normal tests taken within 3 months prior to the study will be accepted if there is no history of acute illness since the time the blood was drawn.
  • Heart disease. (Cannabinoids can reduce heart rate and blood pressure) Patients with heart disease will be excluded based on a history of angina, MI or CHF as well as a clinical exam.
  • Schizophrenia or other Psychotic disorder
  • Severe liver dysfunction. (Patients will be excluded if there is an elevation of any of the baseline liver enzymes)
  • History of untreated non-psychotic emotional disorders.
  • Cognitive impairment.
  • Major illness in another body area.
  • Pregnancy.
  • Nursing mothers.
  • Patients less than 18 years old.
  • History of drug dependency.
  • A known sensitivity to marijuana or other cannabinoid agents

结局指标

主要结局

Visual Analogue Scale Pain Scores

时间窗: Baseline, then at week 2, 4 and 8

Patient is asked to mark their pain from 0 to 10, with 0 = no pain, and 10 = worst pain imaginable

Number of Tender Points

时间窗: At baseline, then at the week 2, 4 and 8 visits

Physician examines by digital palpation for pain at each of the 18 characteristic tender points for fibromyalgia. The number of tender points where pain is reported is recorded

Average Pain Threshold

时间窗: At baseline, then at the 2, 4 and 8 week visits

Patients are examined for pain at the 18 characteristic tender points. The results of all the sites are added and divided by 18 to give an average pain threshold

Fibromyalgia Impact Questionaire

时间窗: At baseline, then again at weeks 2, 4 and 8.

Self-administered questionnaire that evaluates physical function, work status, depression anxiety, sleep, pain, stiffness, fatigue and well-being.

次要结局

未报告次要终点

研究者

发起方
Winnipeg Regional Health Authority
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Lena Galimova

MD, FRCPC

Winnipeg Regional Health Authority

研究点 (2)

Loading locations...

相似试验

A Trial Assessing the Effect of Nabilone on Pain and... | 临床试验